Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.
Yahoo
Skip to navigation
Skip to main content
Skip to right column
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug ·
Barrons.com
·
Dreamstime
